AU2008247388A1 - Matrix marker model and methods for assessing and treating arthritis and related disorders - Google Patents

Matrix marker model and methods for assessing and treating arthritis and related disorders Download PDF

Info

Publication number
AU2008247388A1
AU2008247388A1 AU2008247388A AU2008247388A AU2008247388A1 AU 2008247388 A1 AU2008247388 A1 AU 2008247388A1 AU 2008247388 A AU2008247388 A AU 2008247388A AU 2008247388 A AU2008247388 A AU 2008247388A AU 2008247388 A1 AU2008247388 A1 AU 2008247388A1
Authority
AU
Australia
Prior art keywords
treatment
tnf
probability
rheumatoid arthritis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008247388A
Other languages
English (en)
Inventor
Chenglong Han
Wim Noel
Nathan Vastesaeger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of AU2008247388A1 publication Critical patent/AU2008247388A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Radar Systems Or Details Thereof (AREA)
AU2008247388A 2007-05-03 2008-05-05 Matrix marker model and methods for assessing and treating arthritis and related disorders Abandoned AU2008247388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91572407P 2007-05-03 2007-05-03
US60/915,724 2007-05-03
PCT/US2008/062621 WO2008137828A1 (en) 2007-05-03 2008-05-05 Matrix marker model and methods for assessing and treating arthritis and related disorders

Publications (1)

Publication Number Publication Date
AU2008247388A1 true AU2008247388A1 (en) 2008-11-13

Family

ID=39943976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008247388A Abandoned AU2008247388A1 (en) 2007-05-03 2008-05-05 Matrix marker model and methods for assessing and treating arthritis and related disorders

Country Status (7)

Country Link
US (1) US20100145901A1 (enExample)
EP (1) EP2148934B1 (enExample)
JP (1) JP2010526303A (enExample)
AT (1) ATE550443T1 (enExample)
AU (1) AU2008247388A1 (enExample)
CA (1) CA2686260A1 (enExample)
WO (1) WO2008137828A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3042202A1 (en) 2013-09-03 2016-07-13 Graham, L. Douglas Treatment methods for rheumatoid arthritis
EP4502182A3 (en) * 2018-01-24 2025-07-09 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
JP7593797B2 (ja) * 2020-12-08 2024-12-03 キヤノンメディカルシステムズ株式会社 解析装置、解析システム及び解析方法
WO2023023338A1 (en) * 2021-08-19 2023-02-23 Navidea Biopharmaceuticals, Inc. Compositions and methods for the treatment of rheumatoid arthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187539A (ja) * 1984-09-19 1986-05-02 ヘルギ・ヴアルデイマーソン 慢性関節リウマチ患者の予後を補助するための方法及びこのような患者の病態活動の評価を補助するための方法
EP1212463A2 (en) * 1999-09-08 2002-06-12 The University Of British Columbia Diagnostic and therapeutic methods in autoimmune disease
WO2002022013A1 (en) * 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
US20060141547A1 (en) * 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7702469B2 (en) * 2006-04-10 2010-04-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Systems and methods for predicting an individual's risk of developing rheumatoid arthritis

Also Published As

Publication number Publication date
HK1140797A1 (en) 2010-10-22
EP2148934A1 (en) 2010-02-03
CA2686260A1 (en) 2008-11-13
ATE550443T1 (de) 2012-04-15
JP2010526303A (ja) 2010-07-29
EP2148934B1 (en) 2012-03-21
EP2148934A4 (en) 2010-07-07
US20100145901A1 (en) 2010-06-10
WO2008137828A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
Braun-Moscovici et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Abramson et al. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis
Soriano et al. IL-1β biological treatment of familial Mediterranean fever
JP2008544960A (ja) 炎症傷害の処置および評価
JP2020073470A (ja) 抗ｉｌ２３抗体を使用してクローン病を治療するための方法
EP2171449A2 (en) Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
RU2714919C2 (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
JP2021102644A (ja) 抗ｉｌ−２３抗体を用いた乾癬の治療方法
Kang et al. Efficacy of novel bispecific antibody targeting TNF-α/CXCL10 in the treatment of experimental arthritis
EP2148934B1 (en) Matrix marker model and methods for assessing and treating rheumatoid arthritis
US20200405851A1 (en) Method of diagnosis and treatment of rheumatoid arthritis
Wendling Bone loss in ankylosing spondylitis: can we put the puzzle together?
Miheller et al. Infliximab therapy improves the bone metabolism in fistulizing Crohn’s disease
Park et al. Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis
HK1140797B (en) Matrix marker model and methods for assessing and treating rheumatoid arthritis
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
US20170360888A1 (en) Methods for treating inflammatory arthritis
TW201639596A (zh) 用於治療牛皮癬性關節炎之組合物及方法
AU2010313318A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Kawakami Shin-ya Kawashiri1, 2, 3, Yushiro Endo2, 3, Ayako Nishino2, 3, Momoko Okamoto2, Sosuke Tsuji2, Ayuko Takatani2, Toshimasa Shimizu2, Remi Sumiyoshi2, Tomohiro Koga2, Naoki Iwamoto2, Kunihiro Ichinose2, Mami Tamai2, Hideki Nakamura2, Tomoki Origuchi2, Toshiyuki Aramaki3, Yukitaka Ueki3, Tamami Yoshitama3, Nobutaka Eiraku3, Naoki Matsuoka3, Akitomo Okada3, Keita Fujikawa3, Hiroaki Hamada3, Shuji Nagano3, Yoshifumi Tada3 and
Matsuno Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab
US11674951B2 (en) Methods for identifying a treatment for rheumatoid arthritis
Warzocha et al. Polymyalgia rheumatica-risk factors, pathogenesis, diagnostic methods, treatment-new literature reports
MUÑOZ-VILLAFRANCA et al. Infliximab and Adalimumab Monitoring versus Clinical Control during Maintenance Therapy in Patients with Inflammatory Bowel Disease
TW202508626A (zh) 以針對ＩＬ－２３及ＴＮＦα的抗體的組合來治療克隆氏症之方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application